PodcastsRank #29924
Artwork for On The Pen GLP-1 News

On The Pen GLP-1 News

MedicinePodcastsHealth & FitnessNewsBusiness NewsEN-USunited-statesSeveral times per week
4.9 / 5
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.
Top 59.8% by pitch volume (Rank #29924 of 50,000)Data updated Feb 10, 2026

Key Facts

Publishes
Several times per week
Episodes
172
Founded
N/A
Category
Medicine
Number of listeners
Private
Hidden on public pages

Listen to this Podcast

Pitch this podcast
Get the guest pitch kit.
Book a quick demo to unlock the outreach details you actually need before you hit send.
  • Verified contact + outreach fields
  • Exact listener estimates (not just bands)
  • Reply rate + response timing signals
10 minutes. Friendly walkthrough. No pressure.
Book a demo
Public snapshot
Audience: 8Kโ€“20K / month
Canonical: https://podpitch.com/podcasts/on-the-pen-glp-1-news
Cadence: Active weekly
Reply rate: 35%+

Latest Episodes

Back to top

Eli Lilly Earnings Call Q4 2025 Recap

Wed Feb 04 2026

Listen

Send us a text This week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores what the future of incretin medicine could really look like for patients. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! ๐Ÿค Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join ๐Ÿ‘‰ My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! ๐Ÿ“บ We're Live M/W/F at 11 central: onthepen.tv ๐Ÿ“ฒ Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

More

Send us a text This week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores what the future of incretin medicine could really look like for patients. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! ๐Ÿค Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join ๐Ÿ‘‰ My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! ๐Ÿ“บ We're Live M/W/F at 11 central: onthepen.tv ๐Ÿ“ฒ Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

Key Metrics

Back to top
Pitches sent
11
From PodPitch users
Rank
#29924
Top 59.8% by pitch volume (Rank #29924 of 50,000)
Average rating
4.9
Ratings count may be unavailable
Reviews
108
Written reviews (when available)
Publish cadence
Several times per week
Active weekly
Episode count
172
Data updated
Feb 10, 2026
Social followers
23.7K

Public Snapshot

Back to top
Country
United States
Language
EN-US
Language (ISO)
Release cadence
Several times per week
Latest episode date
Wed Feb 04 2026

Audience & Outreach (Public)

Back to top
Audience range
8Kโ€“20K / month
Public band
Reply rate band
35%+
Public band
Response time band
30+ days
Public band
Replies received
1โ€“5
Public band

Public ranges are rounded for privacy. Unlock the full report for exact values.

Presence & Signals

Back to top
Social followers
23.7K
Contact available
Yes
Masked on public pages
Sponsors detected
Yes
Guest format
Yes

Social links

No public profiles listed.

Demo to Unlock Full Outreach Intelligence

We publicly share enough context for discovery. For actionable outreach data, unlock the private blocks below.

Audience & Growth
Demo to unlock
Monthly listeners49,360
Reply rate18.2%
Avg response4.1 days
See audience size and growth. Demo to unlock.
Contact preview
a***@hidden
Get verified host contact details. Demo to unlock.
Sponsor signals
Demo to unlock
Sponsor mentionsLikely
Ad-read historyAvailable
View sponsorship signals and ad read history. Demo to unlock.
Book a demo

How To Pitch On The Pen GLP-1 News

Back to top

Want to get booked on podcasts like this?

Become the guest your future customers already trust.

PodPitch helps you find shows, draft personalized pitches, and hit send faster. We share enough public context for discovery; for actionable outreach data, unlock the private blocks.

  • Identify shows that match your audience and offer.
  • Write pitches in your voice (nothing sends without you).
  • Move from โ€œmaybe laterโ€ to booked interviews faster.
  • Unlock deeper outreach intelligence with a quick demo.

This show is Rank #29924 by pitch volume, with 11 pitches sent by PodPitch users.

Book a demoBrowse more shows10 minutes. Friendly walkthrough. No pressure.
4.9 / 5
RatingsN/A
Written reviews108

We summarize public review counts here; full review text aggregation is not shown on PodPitch yet.

Frequently Asked Questions About On The Pen GLP-1 News

Back to top

What is On The Pen GLP-1 News about?

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

How often does On The Pen GLP-1 News publish new episodes?

Several times per week

How many listeners does On The Pen GLP-1 News get?

PodPitch shows a public audience band (like "8Kโ€“20K / month"). Book a demo to unlock exact audience estimates and how we calculate them.

How can I pitch On The Pen GLP-1 News?

Use PodPitch to access verified outreach details and pitch recommendations for On The Pen GLP-1 News. Start at https://podpitch.com/try/1.

Which podcasts are similar to On The Pen GLP-1 News?

This page includes internal links to similar podcasts. You can also browse the full directory at https://podpitch.com/podcasts.

How do I contact On The Pen GLP-1 News?

Public pages only show a masked contact preview. Book a demo to unlock verified email and outreach fields.

Quick favor for your future self: want podcast bookings without the extra mental load? PodPitch helps you find shows, draft personalized pitches, and hit send faster.